FDA: Enzon's Abelcet makes unsubstantiated superiority claims

Share this article:
A flash card for Enzon's Abelcet makes unsubstantiated superiority claims and overstates its efficacy, the FDA says. A warning letter says the claims raise concerns because they suggest it is more effective than  demonstrated and encourage its use before other options, even though it is a second-line agent.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters